[go: up one dir, main page]

WO2018148180A3 - Materials and methods for identifying and treating cancer patients - Google Patents

Materials and methods for identifying and treating cancer patients Download PDF

Info

Publication number
WO2018148180A3
WO2018148180A3 PCT/US2018/016990 US2018016990W WO2018148180A3 WO 2018148180 A3 WO2018148180 A3 WO 2018148180A3 US 2018016990 W US2018016990 W US 2018016990W WO 2018148180 A3 WO2018148180 A3 WO 2018148180A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
materials
identifying
treating cancer
cancer patients
Prior art date
Application number
PCT/US2018/016990
Other languages
French (fr)
Other versions
WO2018148180A2 (en
Inventor
Jan Henrik Ter Meulen
Hailing Lu
Frank Hsu
Original Assignee
Immune Design Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune Design Corp. filed Critical Immune Design Corp.
Publication of WO2018148180A2 publication Critical patent/WO2018148180A2/en
Publication of WO2018148180A3 publication Critical patent/WO2018148180A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present disclosure relates to materials and methods for treating cancers associated with expression of tumor antigens, in particular, NY-ES 0-1 -specific cancers, including biomarkers and methods for identifying subjects that will benefit from treatment with tumor antigen-specific cancer therapy.
PCT/US2018/016990 2017-02-07 2018-02-06 Materials and methods for identifying and treating cancer patients WO2018148180A2 (en)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201762455946P 2017-02-07 2017-02-07
US62/455,946 2017-02-07
US201762504312P 2017-05-10 2017-05-10
US62/504,312 2017-05-10
US201762512561P 2017-05-30 2017-05-30
US62/512,561 2017-05-30
US201762514198P 2017-06-02 2017-06-02
US62/514,198 2017-06-02
US201762555333P 2017-09-07 2017-09-07
US62/555,333 2017-09-07

Publications (2)

Publication Number Publication Date
WO2018148180A2 WO2018148180A2 (en) 2018-08-16
WO2018148180A3 true WO2018148180A3 (en) 2018-09-27

Family

ID=61521815

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/016990 WO2018148180A2 (en) 2017-02-07 2018-02-06 Materials and methods for identifying and treating cancer patients

Country Status (1)

Country Link
WO (1) WO2018148180A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011094233A1 (en) * 2010-01-26 2011-08-04 The Johns Hopkins University Methods of disease classification or prognosis for prostate cancer based on expression of cancer/testis antigens
WO2014074785A1 (en) * 2012-11-08 2014-05-15 Ludwig Institute For Cancer Research Ltd. Methods of predicting outcome and treating breast cancer
WO2014172637A1 (en) * 2013-04-18 2014-10-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
WO2016011083A1 (en) * 2014-07-15 2016-01-21 Immune Design Corp. Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector
WO2017044661A1 (en) * 2015-09-09 2017-03-16 Immune Design Corp. Ny-eso-1 specific tcrs and methods of use thereof

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US4902614A (en) 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
CA1283827C (en) 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
US4937190A (en) 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
DE68918494T2 (en) 1988-05-17 1995-03-23 Lubrizol Genetics Inc Herbal ubiquitin promoter system.
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
TW279133B (en) 1990-12-13 1996-06-21 Elan Med Tech
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
US5279552A (en) 1993-01-11 1994-01-18 Anton Magnet Intradermal injection device
US5997501A (en) 1993-11-18 1999-12-07 Elan Corporation, Plc Intradermal drug delivery device
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US5660835A (en) 1995-02-24 1997-08-26 East Carolina University Method of treating adenosine depletion
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
EP0961830A1 (en) 1997-01-29 1999-12-08 Neurosearch A/S EXPRESSION VECTORS AND METHODS FOR $i(IN VIVO) EXPRESSION OF THERAPEUTIC POLYPEPTIDES
EP1019439B1 (en) 1997-10-02 2011-11-16 Altor BioScience Corporation Soluble single-chain t-cell receptor proteins
US6218181B1 (en) 1998-03-18 2001-04-17 The Salk Institute For Biological Studies Retroviral packaging cell line
IL139344A0 (en) 1998-05-19 2001-11-25 Avidex Ltd Soluble t cell receptor
US6494865B1 (en) 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
US6776776B2 (en) 1999-10-14 2004-08-17 Becton, Dickinson And Company Prefillable intradermal delivery device
US7241275B2 (en) 1999-10-14 2007-07-10 Becton, Dickinson And Company Intradermal needle
US20020193740A1 (en) 1999-10-14 2002-12-19 Alchas Paul G. Method of intradermally injecting substances
US6569143B2 (en) 1999-10-14 2003-05-27 Becton, Dickinson And Company Method of intradermally injecting substances
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
WO2001062895A2 (en) 2000-02-24 2001-08-30 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
PT1421115E (en) 2001-08-31 2005-07-29 Avidex Ltd T SOLUVEL CELL RECEIVER
US6971999B2 (en) 2001-11-14 2005-12-06 Medical Instill Technologies, Inc. Intradermal delivery device and method
KR101020724B1 (en) 2002-02-04 2011-03-09 벡톤 디킨슨 앤드 컴퍼니 Apparatus and method for delivering or withdrawing material through skin
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7047070B2 (en) 2002-04-02 2006-05-16 Becton, Dickinson And Company Valved intradermal delivery device and method of intradermally delivering a substance to a patient
US6780171B2 (en) 2002-04-02 2004-08-24 Becton, Dickinson And Company Intradermal delivery device
US7115108B2 (en) 2002-04-02 2006-10-03 Becton, Dickinson And Company Method and device for intradermally delivering a substance
NZ570811A (en) 2002-11-09 2009-11-27 Immunocore Ltd T cell receptor display
US7108679B2 (en) 2004-03-11 2006-09-19 Becton, Dickinson And Company Intradermal syringe and needle assembly
DK2048955T3 (en) 2006-07-21 2013-09-02 California Inst Of Techn TARGETED GENE SUPPLY TO DENDRIT CELL VACCINATION
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
EP3795173A1 (en) 2006-09-26 2021-03-24 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US8119772B2 (en) 2006-09-29 2012-02-21 California Institute Of Technology MART-1 T cell receptors
SI2770061T1 (en) 2009-07-24 2019-02-28 Immune Design Corp. Non-integrating lentiviral vectors
SG193591A1 (en) 2011-03-23 2013-10-30 Hutchinson Fred Cancer Res Method and compositions for cellular immunotherapy
BR112013025799A2 (en) 2011-04-08 2016-12-20 Immune Design Corp method for inducing an immune response in a subject, and, preparing
US8323662B1 (en) 2012-03-30 2012-12-04 Immune Design Corp. Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein
BR112014024449A2 (en) 2012-03-30 2017-08-08 Immune Design Corp composition, method of generating a pseutipated lentiviral vector particle, and, lentiviral vector particle.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011094233A1 (en) * 2010-01-26 2011-08-04 The Johns Hopkins University Methods of disease classification or prognosis for prostate cancer based on expression of cancer/testis antigens
WO2014074785A1 (en) * 2012-11-08 2014-05-15 Ludwig Institute For Cancer Research Ltd. Methods of predicting outcome and treating breast cancer
WO2014172637A1 (en) * 2013-04-18 2014-10-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
WO2016011083A1 (en) * 2014-07-15 2016-01-21 Immune Design Corp. Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector
WO2017044661A1 (en) * 2015-09-09 2017-03-16 Immune Design Corp. Ny-eso-1 specific tcrs and methods of use thereof

Also Published As

Publication number Publication date
WO2018148180A2 (en) 2018-08-16

Similar Documents

Publication Publication Date Title
MX2019011148A (en) Treatment methods.
MX2024013523A (en) Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
MX2018008426A (en) Anti-egfr combinations for treating tumors.
MX2020008882A (en) Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies.
EP3964527A3 (en) Combination therapy for cancer
MX2018014175A (en) ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE.
MX2018008427A (en) Anti-cd20 combinations for treating tumors.
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
MX2022008868A (en) Treatment of cancer with tg02.
MX2016004489A (en) Systems and methods for treating cancer and/or augmenting organ function.
EA201691866A1 (en) TUMOR LYMPHOCYTES PERMITTING FOR ADAPTIVE CELL THERAPY
NZ631197A (en) Anti sez6 antibodies and methods of use
TW201613647A (en) Compounds and compositions for treating HER2 positive tumors
NZ756730A (en) Combination therapy with an anti-axl antibody-drug conjugate
MX2016002051A (en) Methods and kits for the molecular subtyping of tumors.
MX2019006331A (en) Methods of treating cancer using anti-pd-l1 antibodies and antiandrogens.
AU2015249633A8 (en) Methods of treating early breast cancer with Trastuzumab-MCC-DM1 and Pertuzumab
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
MX2015012922A (en) Cancer treatment using antibodies that bing cell surface grp78.
PH12020551968A1 (en) Anti-sez6 antibody drug conjugates and methods of use
MX2019008233A (en) Targeted doxorubicin-gold nanoconjugates for tumor therapy.
MX2018007817A (en) Novel anti-mmp16 antibodies and methods of use.
MX2018007818A (en) Novel anti-upk1b antibodies and methods of use.
HK1250626A1 (en) Combination treatments with seribantumab
PH12021551352A1 (en) Anti-periostin antibodies and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18708000

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18708000

Country of ref document: EP

Kind code of ref document: A2